Get the Stockscreener App
3.17
2.46%
-0.08
Purple Biotech Ltd Adr stock is traded at $3.17, with a volume of 6,681.
It is down -2.46% in the last 24 hours and down -10.45% over the past month.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219 and CM24.
See More
Previous Close:
$3.25
Open:
$3.23
24h Volume:
6,681
Relative Volume:
0.01
Market Cap:
$8.19M
Revenue:
-
Net Income/Loss:
$-19.88M
P/E Ratio:
-3.4835
EPS:
-0.91
Net Cash Flow:
$-19.93M
1W Performance:
+2.26%
1M Performance:
-10.45%
6M Performance:
-60.15%
1Y Performance:
-77.49%
1-Day Range:
$3.07
$3.33
1-Week Range:
$3.07
$3.4755
52-Week Range:
$2.00
$20.60
Purple Biotech Ltd Adr Stock (PPBT) Company Profile
Compare PPBT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PPBT
Purple Biotech Ltd Adr
|
3.17 | 8.19M | 0 | -19.88M | -19.93M | -0.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Purple Biotech Ltd Adr Stock (PPBT) Latest News
Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial - GlobeNewswire Inc.
PPBT Stock Surges 150% on Superior Efficacy of PDAC Combo Therapy - Yahoo Finance
Why Purple Biotech (PPBT) Stock Is Getting Hammered - Benzinga
Purple Biotech Reports Third Quarter 2024 Financial Results - Yahoo Finance
U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.65% - MSN
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.65% - MSN
PPBT stock touches 52-week low at $3.52 amid market challenges - Investing.com India
PPBT stock touches 52-week low at $5.89 amid market challenges - Investing.com India
Purple Biotech price target raised by H.C. Wainwright, maintains Buy rating - Investing.com India
PPBT stock touches 52-week high at $8.02 amid market fluctuations - Investing.com
Ratio Review: Analyzing Purple Biotech Ltd ADR (PPBT)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
What Makes Purple Biotech (PPBT) a New Buy Stock - Yahoo Finance
Purple Biotech stock target cut on trial cohort issue - Investing.com
95 Promising Stocks You Can Currently Buy for Less Than $5 Per Share - GOBankingRates
Purple Biotech stock retains Buy rating from H.C. Wainwright - Investing.com
Why Purple Biotech (PPBT) Shares Are Trading Lower - Benzinga
Here's Why Purple Biotech Ltd. Sponsored ADR (PPBT) Could be Great Choice for a Bottom Fisher - Yahoo Finance
Best Penny Stocks Under $1 To Buy Now - AOL
A new, genetically modified purple tomato may hit the grocery market stands - CNN
The Daily Biotech Pulse: DermTech Soars On Contract, Fluidigm Plunges On Earnings, Decision Day For Regeneron, Bioventus Debuts - Benzinga
The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study - Yahoo Finance
Purple Biotech (PPBT) Stock Price, News & Analysis - MarketBeat
Market Data Center - Barron's
The FDA Just Approved Kitov's ConsensiNow What? (NASDAQ:PPBT) - Seeking Alpha
ADVFNFree stock and cryptocurrency prices, charts, market news and streaming real-time quotes. - ADVFN
Purple Biotech Ltd Adr Stock (PPBT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):